(CercleFinance.com) – Valneva today announced the initiation of a clinical trial to evaluate its inactivated whole virus COVID-19 vaccine candidate, VLA2001, as a heterologous booster.
This will be the first clinical trial to provide booster data with VLA2001 in people who have either been primed with a messenger RNA vaccine or have been naturally infected with the COVID-19 virus.
If positive, the data could support a possible use of VLA2001 as a booster vaccine, subject to obtaining regulatory recommendations and clearances.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
